Free Trial

Extendicare Inc. (TSE:EXE) Receives Consensus Rating of "Moderate Buy" from Brokerages

Extendicare logo with Medical background

Key Points

  • Extendicare Inc. has received a consensus recommendation of "Moderate Buy" from five brokerages, with three holding, one buying, and one assigning a strong buy rating.
  • The company's average 12-month price target is projected at C$14.15, with notable upgrades from various analysts, raising it to as high as C$16.10.
  • Extendicare recently announced a quarterly dividend of $0.042 to be paid on September 15th, resulting in an annualized yield of 1.3% and a payout ratio of 61.20%.
  • Looking to export and analyze Extendicare data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Shares of Extendicare Inc. (TSE:EXE - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five research firms that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation, one has given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is C$14.15.

Several analysts have commented on EXE shares. TD Securities raised their target price on shares of Extendicare from C$13.00 to C$15.00 and gave the stock a "hold" rating in a report on Thursday, May 22nd. BMO Capital Markets raised their target price on shares of Extendicare from C$13.50 to C$14.50 in a research note on Monday, May 12th. National Bankshares boosted their target price on shares of Extendicare from C$15.45 to C$16.10 and gave the company an "outperform" rating in a research report on Friday, August 8th. Finally, National Bank Financial raised Extendicare to a "strong-buy" rating in a research note on Wednesday, July 16th.

Check Out Our Latest Report on EXE

Extendicare Trading Down 0.6%

Extendicare stock traded down C$0.08 during midday trading on Tuesday, hitting C$13.40. 12,007 shares of the stock were exchanged, compared to its average volume of 186,068. The company has a fifty day simple moving average of C$13.40 and a two-hundred day simple moving average of C$13.09. Extendicare has a 52 week low of C$8.17 and a 52 week high of C$15.24. The stock has a market capitalization of C$1.12 billion, a PE ratio of 17.09 and a beta of 1.26. The company has a quick ratio of 0.98, a current ratio of 0.62 and a debt-to-equity ratio of 283.02.

Extendicare Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 15th. Shareholders of record on Friday, August 29th will be issued a dividend of $0.042 per share. This represents a $0.17 dividend on an annualized basis and a dividend yield of 1.3%. Extendicare's payout ratio is 61.20%.

About Extendicare

(Get Free Report)

Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.

Featured Stories

Analyst Recommendations for Extendicare (TSE:EXE)

Should You Invest $1,000 in Extendicare Right Now?

Before you consider Extendicare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.

While Extendicare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Follow the Money: 5 Stocks Institutions Are Buying NOW
Strong Earnings? Market Says NVIDIA-Level Growth or Be Forgotten
Palantir’s Soaring Valuation—Justified or Overhyped?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines